Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.

@article{Hardeland2009TasimelteonAM,
  title={Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.},
  author={R{\"u}diger Hardeland},
  journal={Current opinion in investigational drugs},
  year={2009},
  volume={10 7},
  pages={691-701}
}
Tasimelteon, developed by Vanda Pharmaceuticals Inc under license from Bristol-Myers Squibb Co, is a melatonin receptor agonist. Because of the high density of melatonin receptors in the circadian pacemaker, the suprachiasmatic nucleus, melatonergic actions can phase-shift circadian rhythms and promote sleep. Tasimelteon was effective in reducing sleep onset latency (in phase II and III clinical trials) and in resetting the circadian melatonin rhythm (in phase II trials), which indicated its… CONTINUE READING
8 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…